Stay updated with breaking news from Laras Sullivan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s...
Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates and other oncology modalitiesBOSTON, Nov. 28, 2023 -- Pyxis Oncology, Inc. , a...
PYX-201 Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 : Phase 1 trial now focusing on NSCLC and other tumor types; data expected 2H 2024. Cash runway...
07.11.2023 - PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immunotherapy ...
BOSTON, Sept. 27, 2023 -- Pyxis Oncology, Inc. , a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for...